Mubadala Bio完成全面收购Al Ittihad药店和全球医疗供应链, 提升阿联酋的保健复原力。 Mubadala Bio completes full acquisition of Al Ittihad Drug Store and Global Medical Supply Chain, boosting UAE’s healthcare resilience.

Mubadala Bio已完成从Yas Holding公司全面收购Al Ittihad药店和全球医疗供应链的工作,最后敲定了一项交易,于2024年底以80%的购买开始。 Mubadala Bio has completed its full acquisition of Al Ittihad Drug Store and Global Medical Supply Chain from Yas Holding, finalizing a deal that began with an 80% purchase in late 2024. 推动Mubadala Bio战略在阿联酋建立纵向综合生命科学平台, 将生物制药制造业与医药物流相结合, The move advances Mubadala Bio’s strategy to create a vertically integrated life sciences platform in the UAE by combining biopharmaceutical manufacturing with pharmaceutical logistics. 一体化的目的是提高供应链的效率,加强国家药物安全,支持阿联酋建立一个有复原力、创新驱动的保健体系的目标。 The integration aims to improve supply chain efficiency, strengthen national drug security, and support the UAE’s goal of building a resilient, innovation-driven healthcare system. Mubadala Bio公司和Yas Holding公司的官员都强调了收购公司在加强国家保健供应链的可靠性和复原力方面的作用。 Officials from both Mubadala Bio and Yas Holding emphasized the acquisition’s role in enhancing the reliability and resilience of the national healthcare supply chain.